MeSH D012140 - respiratory tract diseases
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D012140:Â
Respiratory tract diseases
D001982:Bronchial diseases
0 Companies
0 Drugs
Success rate
D002925:Ciliary motility disorders
0 Companies
0 Drugs
Success rate
D007818:Laryngeal diseases
0 Companies
0 Drugs
Success rate
D008171:Lung diseases
D009668:Nose diseases
0 Companies
0 Drugs
Success rate
D010995:Pleural diseases
0 Companies
0 Drugs
Success rate
D012120:Respiration disorders
D012130:Respiratory hypersensitivity
D012141:Respiratory tract infections
D012142:Respiratory tract neoplasms
0 Companies
0 Drugs
Success rate
D013896:Thoracic diseases
0 Companies
0 Drugs
Success rate
D014133:Tracheal diseases
0 Companies
0 Drugs
Success rate
D015619:Respiratory system abnormalities
0 Companies
0 Drugs
Success rate
D015769:Respiratory tract granuloma
0 Companies
0 Drugs
Success rate
D016156:Respiratory tract fistula
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Roche | Pirfenidone | Esbriet |  | 2011-02-27 | $749.525 M | Y2022 |
| AstraZeneca | Formoterol, Glycopyrrolate | Bevespi Aerosphere | 2030-05-28 | 2016-04-25 |  |  |
| Budesonide, Formoterol, Glycopyrrolate | Breztri Aerosphere | 2030-05-28 | 2020-07-23 | $19 M | Y2024 |
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
100%7/7
Phase 2
37%7/19
Phase 3
8%2/25
Approved: 2Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use